A comparative study of the therapeutic effect of probucol and pravastatin on xanthelasma

Journal of Dermatology

Volumn 23, Issue 9, 1996, Pages 598-602

  Fujita, Masaru ^a,c   Shirai, Kohji ^b  

^a TOHO UNIVERSITY   (Japan)

^b CHIBA UNIVERSITY   (Japan)

^c Funabashi Municipal Medical Center   (Japan)

Author keywords

pravastatin; probucol; therapy; xanthelasma

Indexed keywords

PRAVASTATIN; PROBUCOL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; DISEASE ASSOCIATION; DRUG EFFICACY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; XANTHOMA;

EID: 0029964934     PISSN: 03852407     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1346-8138.1996.tb02661.x     Document Type: Article

References (13)

1. Harris RS, Gilomore HR, Bricker LA, Kiem IM, Rubin E: Long-term oral administration of probucol [4,4-(isopropyridenedithio) bis (2,6-di-t-butylphenol)] (DH-581) in the management of hypercholesterolemia, J Am Geriatric Soc, 22: 167-175, 1974.
2. Yamamoto A, Matsuzawa Y, Kishino B, Hayashi R, Hirobe K, Kikkawa T: Effects of probucol on homogeneous cases of familial hypercholesterolemia, Atherosclerosis, 48: 157-166, 1983.
3. Watanabe A, Sakai T, Wakasugi T, et al: Effects of long-term probucol treatment on serum lipids, lipoprotein lipids and skin xanthomas in heterozygous familial hypercholesterolemic patients, J Jpn Atheroscler Soc, 11: 597-602, 1983.
4. Baker SG, Joffe BI, Mendelsohn D, Seftel HC: Treatment of homozygous familial hypercholesterolemia with probucol, S Afr Med J, 62: 7-11, 1982.
5. The probucol clinical research group: Effects of probucol on xanthelasma regression, Nishinihon J Dermatol, 52: 1230-1238, 1990. (in Japanese)
6. Watanabe Y, Ito T, Shiomi M, et al: Preventive effect of pravastatin sodium, a potent inhibitor of 3-hydroxy-3 methylglutaryl coenzyme A reductase, on coronary atherosclerosis and xanthoma in WHHL rabbits, Biochimica Biophysica Acta, 960: 294-312, 1988.
7. The CS-514 research group: Study on the clinical efficacy of CS-514 (Pravastatin) in long-term treatment on hypercholesterolemia, Rinshouiyaku, 4: 409-437, 1988. (in Japanese)
8. Yamamoto A, Matsuzawa Y, Yokoyama S, Funahashi T, Yamamura T, Kishino B: Effects of probucol on xanthoma regression in familial hypercholesterolemia, Am J Cardiol, 57: 29H-35H, 1986.
9. Franceschuni G, Sirtori M, Vaccarino V, et al: Mechanism of HDL reduction after probucol, changes in HDL subfractions and increased reverse cholesteryl ester transfer, Atherosclerosis, 9: 462-469, 1989.
10. Matsuzawa Y, Yamashita S, Funahashi T, Yamamoto A, Tarui S: Selective reduction of cholesterol in HDL2 fraction by probucol in familial hypercholesterolemia and hyper HDL2 cholesterolemia with abnormal cholesterol ester transfer, Am J Cardiol, 62: 66B-72B, 1988.
11. Fujita M, Utsuki K, Okamoto S, Shirai K, Saito K, Yoshida S: Lipid metabolic disturbances in xanthelasma: Evaluation of serum total cholesterol, HDL-cholesterol and apolipoproteins, Jpn J Dermatol, 103: 1157-1163, 1993. (in Japanese)
12. Yamamoto A: Plasma lipids and lipoproteins in patients with xanthelasma: Significance of low levels of high-density lipoproteins in the normolipemic patients, Jpn J Dermatol, 96: 1669-1675, 1986. (in Japanese)
13. Fujita M, Utsugi K, Suzuki Y, Shirai K: Drug therapy of xanthelasma, Hifubyo-shinryou, 17: 397-400, 1995. (in Japanese)